BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9275651)

  • 1. [Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder].
    Yu D; Liu F; Liang Z
    Zhonghua Bing Li Xue Za Zhi; 1996 Aug; 25(4):202-5. PubMed ID: 9275651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of the expression of P21, P53, P185 proteins and the mutation of ras, p53 genes in colorectal adenoma and carcinoma].
    Liang Z; Liu F; Luo Y
    Zhonghua Bing Li Xue Za Zhi; 1995 Dec; 24(6):352-5. PubMed ID: 8732090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of P21, p53 and proliferating cell nuclear antigen in human bladder cancer].
    Ding Q; Zhang Y; Sun X
    Zhonghua Bing Li Xue Za Zhi; 1997 Aug; 26(4):211-3. PubMed ID: 10072865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation and bcl-2 expression in transitional cell carcinoma of the urinary bladder.
    Wu TT; Lee YH; Huang JK
    Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):9-14. PubMed ID: 11310375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The correlation between expression of oncogene protein products p53, p21, p185 and cell differentiation and prognosis in rhabdomyosarcoma].
    Lai R; Luo Z; An J
    Zhonghua Bing Li Xue Za Zhi; 1997 Feb; 26(1):35-7. PubMed ID: 10072848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The molecular biology of bladder carcinoma].
    Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts.
    Masui T; Mann AM; Macatee TL; Okamura T; Garland EM; Fujii H; Pelling JC; Cohen SM
    Cancer Res; 1991 Jul; 51(13):3471-5. PubMed ID: 2054786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated H-ras gene mutations in transitional cell carcinoma of urinary bladder in a Kashmiri population.
    Pandith AA; Shah Z; Rasool R; Dil-Afroze ; Yousuf A; Parveen N; Wani S; Siddiqi M
    Tumori; 2010; 96(6):993-8. PubMed ID: 21388064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
    Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
    Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 Gene mutations in superficial bladder cancer.
    Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
    Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater.
    Zhao B; Kimura W; Futakawa N; Muto T; Kubota K; Harihara Y; Takayama T; Makuuchi M
    Am J Gastroenterol; 1999 Aug; 94(8):2128-34. PubMed ID: 10445539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
    Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
    Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
    Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
    Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
    Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
    J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.